<DOC>
<DOCNO>EP-0613472</DOCNO> 
<TEXT>
<INVENTION-TITLE>
10-ACYL-DIBENZ(B,F) (1,4)-OXAZEPINES AND THEIR THIAZEPINES ANALO GUES USEFUL AS PROSTAGLANDIN ANTAGONISTS.
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3155	A61K3155	A61K31554	A61K31554	A61P100	A61P100	A61P300	A61P302	A61P900	A61P906	A61P1100	A61P1100	A61P1300	A61P1302	A61P1500	A61P1500	A61P2500	A61P2504	A61P2508	A61P4300	A61P4300	C07D26700	C07D26720	C07D28100	C07D28116	C07D41300	C07D41312	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	C07D	C07D	C07D	C07D	C07D	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61K31	A61K31	A61P1	A61P1	A61P3	A61P3	A61P9	A61P9	A61P11	A61P11	A61P13	A61P13	A61P15	A61P15	A61P25	A61P25	A61P25	A61P43	A61P43	C07D267	C07D267	C07D281	C07D281	C07D413	C07D413	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The present invention provides substituted dibenzoxazepine compounds of formula (I), which are useful as analgesic agents for the treatment of pain, pharmaceutical compositions comprising a therapeutically-effective amount of a compound of formula (I) in combination with a pharmaceutically-acceptable carrier, and a method for eliminating or ameliorating pain in an animal comprising administering a therapeutically-effective amount of a compound of formula (I) to the animal.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
SEARLE 
&
 CO
</APPLICANT-NAME>
<APPLICANT-NAME>
G.D. SEARLE 
&
 CO.
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
CHANDRAKUMAR NIZAL SAMUEL
</INVENTOR-NAME>
<INVENTOR-NAME>
HAGEN TIMOTHY JOSEPH
</INVENTOR-NAME>
<INVENTOR-NAME>
HALLINAN E ANN
</INVENTOR-NAME>
<INVENTOR-NAME>
PITZELE BARNETT SYLVAIN
</INVENTOR-NAME>
<INVENTOR-NAME>
RAO SHASHIDHAR N
</INVENTOR-NAME>
<INVENTOR-NAME>
CHANDRAKUMAR, NIZAL, SAMUEL
</INVENTOR-NAME>
<INVENTOR-NAME>
HAGEN, TIMOTHY, JOSEPH
</INVENTOR-NAME>
<INVENTOR-NAME>
HALLINAN, E., ANN
</INVENTOR-NAME>
<INVENTOR-NAME>
PITZELE, BARNETT, SYLVAIN
</INVENTOR-NAME>
<INVENTOR-NAME>
RAO, SHASHIDHAR, N.
</INVENTOR-NAME>
</INVENTORS>
<DESCRIPTION>
10-ACYL-DIBENZ(B,F)(1,4)-0XAZEPINES AND THEIR THIAZEPINES ANALOGUES USEFUL PROSTAGLANDIN ANTAGONISTSBACKGROUND OF THE INVENTION (1) Field of the InventionThe present invention generally relates to compounds having pharmacological activity which are useful as pharmacological agents and, more particularly, as analgesic agents for the treatment of pain, to pharmaceutical compositions containing one or more of these compounds, and to methods of treatment employing these compounds. More particularly, the present invention concerns substituted dibenzoxazepine compounds, pharmaceutical compositions containing one or more of these compounds in combination with a pharmaceutically-acceptable carrier, and methods of treating pain employing these compounds. Analgesic compounds are agents which alleviate pain without causing a loss of consciousness and, thus, which are useful for treating pain and, often, for reducing inflammation.The major classes of analgesic compounds include narcotic analgesics, or opiates, compounds which alleviate pain and induce sleep, and analgesic- antipyretic compounds, compounds which alleviate pain and reduce fever, such as salicylates.Although the efficacy of opiates in relieving pain is well established, the associated addiction liability of opiates is a distinct disadvantage of these compounds.While salicylate and salicylate-like agents (non- steroidal antiinflammatory agents or NSAIDS) are also efficacious in relieving pain, they often exhibit undesirable side effects, such as gastrointestinal irritation, as with aspirin, allergic response, as with aspirin, and/or liver toxicity with extended use, as with acetaminophen. The compounds of the present invention are neither opiates nor salicylates, and represent another class of compounds which are useful as analgesic agents. 

 (2) Description of the Related ArtU.S. Patent Nos. 4,559,336 and 4,614,617 (a continuation-in-part of U.S. 4,559,336) disclose 8-chlorodibenz[b,f] [1,4]oxazepine-10(11H)-carboxyiic acid, 2-(sulfinyl- and sulfonyl-containing acyl) ydrazides, and intermediates thereof.U.S. Patent No. 3,534,019 discloses hydrazides of dibenzoxazepine-, dibenzothiazepine- and dibenzodiazepine-carboxylic acids. U.S. Patent No. 3,624,104 discloses aralkanoyl derivatives of dibenzoxazepine-N-carboxylic acid hydrazide compounds.U.S. Patent No. 3,989,719 discloses N,N'-diacyl hydrazines. U.S. Patents Nos. 3,917,649 and 3,992,375 (a divisional of U.S. Patent No. 3,917,649) disclose dibenzoxazepine N-carbox lic acid hydrazine compounds.U.S.
</DESCRIPTION>
<CLAIMS>
WHAT IS CLAIMED IS:
1. A compound having a structure of the formula:
or a pharmaceutically-acceptable salt, ester or amide thereof , wherein:
O
R-
1
- is hydrogen, halogen, hydroxy or -O-C 'I-R3,*
R
2
 is hydrogen, halogen or trifluoromethyl;
R
3
 is hydrogen or alkyl;
W is -CH=CH-, -(CH
2
)
2
- or -C≡C-;
X is oxygen or -NH-;
n is an integer of from 0 to 5; o o
Z is oxygen, sulfur, -S- or -S-
0 II 


 Y is hydrogen, alkyl, hydroxy, alkoxy, aryl,
H CH, heteroaryl, -NH
2
, -N I-CH
3
, or -NI-CH
3
,
with the proviso that Y is not hydroxy, alkoxy,
H CH,
-NH
2
, -N I-CH
3
 or -NI-CH
3
 when n is 0.
2. A compound of Claim 1 wherein R
1
 and R
2
 are each independently hydrogen or halogen.
3. A compound of Claim 2 wherein R
1
 is hydrogen and R
2
 is halogen.
4. A compound of Claim 3 wherein R
2
 is chlorine.
5. A compound of Claim 4 wherein n is an integer of from 0 to 3.
6. A compound of Claim 5 wherein Y is alkyl,
H hydroxy, alkoxy, aryl, heteroaryl, -NH
2
, -N I-CH
3
 or
CH, 1 
J
-N-CH
3
.
7. A compound of Claim 6 wherein Y is methyl, ethyl, propyl, hydroxy, methoxy, ethoxy, phenyl,
CH, thiophene, furan, pyridine or -N I-CH
3
 and Z is oxygen. 


 8. A compound of Claim 7 wherein Y is methyl,
CH, ethyl, propyl, hydroxy, methoxy, pyridine or -N I-CH
3
.
9. A compound of Claim 8 wherein Y is methyl,
CH, hydroxy, pyridine or -N I-CH
3
.
10. A compound of Claim 1, wherein the compound is:
11. A compound of Claim 1, wherein the compound is:
12. A compound of Claim 1, wherein the compound s :
13. A compound of Claim 1, wherein the compound s:
14. A compound of Claim 1, wherein the compound is:
15. A compound of Claim 1, wherein the compound s:
16. A compound of Claim 1, wherein the compound is:
17. A compound of Claim 1, wherein the compound is:
18. A compound of Claim 1, wherein the compound is:

 19. A compound of Claim 1, wherein the compound is:
20. A compound of Claim 1, wherein the compound is:
HCl 


 21. A compound of Claim 1 wherein the compound is:
4-(8-chloro-10,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butanoic acid;
Butyl 4-(8-chloro-10,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butenoate;
Butyl 4-(.8-chloro-10,11-dihydrodibenz[b,f]
- oxazepin-10-yl)-4-oxo-2E-butenoate;
N-butyl-4-(8-chloro-10,ll-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butenamide;
4-(8-chloro-10,ll-dihydrodibenz[b,f]oxazepin- 10-yl)-4-oxo-N-(2-pyridinylmethyl)-2Z-butenamide;
Methyl 4-(8-chloro-10,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2E-butenoate;
4-(8-chloro-10,11-dihydrodibenz[b,f]oxazepin-10-yl)-
N-[2-(dimethylamino)ethyl]-4-oxo-2E-butenamide, monohydrochloride;
8-chloro-γ-oxo-N-(4-pyridinylmethy1)dibenz[b,f]- [l,4]
oxazepine-10(11)-butanamide;
8-chloro-N-oxo-N-[2-(dimethylamino)ethyl]-γ-oxodibenz- [b,f]
 [l,4]oxazepine-10(11)-butanamide;
4-(8-chloro-10,11-dihydrodibenz[b,f]oxazepin-10-yl)- 4-oxo-N-(4-pyridinylmethy1)-2E-butenamide; or
4-(8-chloro-10,11-dihydrodibenz[b,f]oxazepin-10-yl)-
4-oxo-N-(4-pyridinylmethy1)-2E-butenamide, monohydrochloride. 


 22. A pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a therapeutically-effective amount of a compound of Claim 1.
23. The pharmaceutical composition of Claim 22 wherein the compound is:
4-(8-chloro-lO,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butanoic acid;
Butyl 4-(8-chloro-10,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butenoate;
Butyl 4-(8-chloro-lO,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2E-butenoate;
N-butyl-4-(8-chloro-lO,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butenamide;
Methyl 4-(8-chloro-lO,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2E-butenoate;
4-(8-chloro-lO,11-dihydrodibenz[b,f]oxazepin-10-yl)-
N-[2-(dimethylamino) thyl]-4-oxo-2E-butenamide, monohydrochloride;
8-chloro-γ-oxo-N-(4-pyridinylmethyl)dibenz[b,f]- [1,4]
oxazepine-10(11)-butanamide;
8-chloro-N-oxo-N-[2-(dimethylamino)ethyl]-γ-oxodibenz- [b, ]
[1,4]oxazepine-10(11)-butanamide;
4-(8-chloro-lO,11-dihydrodibenz[b,f]oxazepin-10-yl)- 4-oxo-N-(4-pyridinylmethyl)-2E-butenamide; or 



 4-(8-chloro-10,11-dihydrodibenz[b,f]oxazepin-10-yl)-
4-oxo-N-(4-pyridinylmethyl)-2E-butenamide, monohydrochloride.
24. A method for treating central nervous disorders in an animal comprising administering to said animal a therapeutically-effective amount of a compound of Claim 1.
25. The method of Claim 24 wherein the compound is:
4-(8-chloro-10,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butanoic acid;
Butyl 4-(8-chloro-10,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butenoate;
Butyl 4-(8-chloro-10,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2E-butenoate;
N-butyl-4-(8-chloro-10,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butenamide;
Methyl 4-(8-chloro-l0, 11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2E-butenoate;
4-(8-chloro-lO, 11-dihydrodibenz[b,f]oxazepin-10-yl)-
N-[2-(dimethylamino)ethyl]- -oxo-2E-butenamide, monohydrochloride.
8-chloro-γ-oxo-N-(4-pyridinylmethyl)dibenz[b,f]- [1,4]
oxazepine-10(11)-butanamide;
8-chloro-N-oxo-N-[2-(dimethylamino)ethyl]-γ-oxodibenz- [b,f]
 [1,4]oxazepine-10(11)-butanamide; 



 4-(8-chloro-10,11-dihydrodibenz[b,f]oxazepin-10-yl)- 4-oxo-N-(4-pyridinylmethyl)-2E-butenamide; or
4-(8-chloro-10,ll-dihydrodibenz[b,f]oxazepin-10-yl) 4-oxo-N-(4-pyridinylmethyl)-2E-butenamide, monohydrochloride.
26. A method for treating pain in an animal comprising administering to said animal a therapeutically-effective amount of a compound of Claim 1.
27. The method of Claim 26 wherein the compound
4-(8-chloro-lO,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butanoic acid;
Butyl 4-(8-chloro-lO,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butenoate;
Butyl 4-(8-chloro-lO,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2E-butenoate;
N-butyl-4-(8-chloro-lO ,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butenamide;
Methyl 4-(8-chloro-10,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2E-butenoate;
4-(8-chloro-lO,11-dihydrodibenz[b,f]oxazepin-10-yl) N-[2-(dimethylamino)ethyl]
-4-oxo-2E-butenamide, monohydrochloride;
8-chloro-γ-oxo-N-(4-pyridinylmethyl)dibenz[b,f]- [1,4]
oxazepine-10(11)-butanamide; 


 8-chloro-N-oxo-N-[2-(dimethylamino)ethyl]-γ-oxodibenz- [b,f]
 [1,4]oxazepine-10(11)-butanamide;
4-(8-chloro-10,11-dihydrodibenz[b,f]oxazepin-10-yl) 4-oxo-N-(4-pyridinylmethyl)-2E-butenamide; or
4-(8-chloro-10,11-dihydrodibenz[b,f]oxazepin-10-yl) 4-oxo-N-(4-pyridinylmethyl)-2E-butenamide, monohydrochloride.
28. A method for treating asthma in an animal comprising administering to said animal a therapeutically-effective amount of a compound of Claim 1.
29. The method of Claim 28 wherein the compound is:
4-(8-chloro-10,11-dihydrodibenz[b,f]oxazepin-10-yl) N-[2-(dimethylamino)ethyl]
-4-oxo-2E-butenamide, monohydrochloride;
4-(8-chloro-lO,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butanoic acid;
Butyl 4-(8-chloro-10,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butenoate;
Butyl 4-(8-chloro-10,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2E-butenoate;
N-butyl-4-(8-chloro-lO,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butenamide; 



 Methyl 4-(8-chloro-10,ll-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2E-butenoate;
4-(8-chloro-10,ll-dihydrodibenz[b,f]oxazepin-10-yl)-
N-[2-(dimethylamino)ethyl]-4-oxo-2E-butenamide, monohydrochloride;
8-chloro-γ-oxo-N-(4-pyridinylmethyl)dibenz[b,f]- [1,4]
oxazepine-10(11)-butanamide;
8-chloro-N-oxo-N-[2-(dimethylamino)ethyl]-γ-oxodibenz- [b,f]
 [1,4]oxazepine-10(11)-butanamide;
4-(8-chloro-10 ,11-dihydrodibenz[b,f]oxazepin-10-yl)- 4-oxo-N-(4-pyridinylmethyl)-2E-butenamide; or
4-(8-chloro-lO,11-dihydrodibenz[b,f]oxazepin-10-yl)-
4-oxo-N-(4-pyridinylmethyl)-2E-butenamide, monohydrochloride.
30. A method for treating enuresis in an animal comprising administering to said animal a therapeutically-effective amount of a compound of Claim 1.
31. The method of Claim 30 wherein the compound is:
4-(8-chloro-lO,11-dihydrodibenz[b,f]oxazepin-10-yl)-
N-[2-(dimethylamino) thyl]-4-oxo-2E-butenamide, monohydrochloride;
4-(8-chloro-lO,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butanoic acid;
Butyl 4-(8-chloro-lO,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butenoate; 



 Butyl 4-(8-chloro-10,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2E-butenoate;
N-butyl-4-(8-chloro-10,ll-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butenamide;
Methyl 4-(8-chloro-lO,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2E-butenoate;
4-(8-chloro-10,11-dihydrodibenz[b,f]oxazepin-10-yl)-
N-[2-(dimethylamino)ethyl]-4-oxo-2E-butenamide, monohydrochloride;
8-chloro-γ-oxo-N-(4-pyridinylmethy1)dibenz[b,f]- [1,4]
oxazepine-10(11)-butanamide;
8-chloro-N-oxo-N-[2-(dimethylamino)ethyl]-γ-oxodibenz- [b,f]
 [l,4]oxazepine-10(11)-butanamide;
4-(8-chloro-10,11-dihydrodibenz[b,f]oxazepin-10-yl)- 4-oxo-N-(4-pyridinylmethyl)-2E-butenamide; or
4-(8-chloro-10,11-dihydrodibenz[b,f]oxazepin-10-yl)-
4-oxo-N-(4-pyridinylmethyl)-2E-butenamide, monohydrochloride.
32. A method for treating arrhythmia in an animal comprising administering to said animal a therapeutically-effective amount of a compound of Claim 1.
33. The method of Claim 32 wherein the compound is:
4-(8-chloro-lO,11-dihydrodibenz[b,f]oxazepin-10-yl)-
N-[2-(dimethylamino)ethyl]-4-oxo-2E-butenamide, monohydrochloride; 



 4-(8-chloro-lO, l-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butanoic acid;
Butyl 4-(8-chloro-lO,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butenoate;
Butyl 4-(8-chloro-lO,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2E-butenoate;
N-butyl-4-(8-chloro-lO,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butenamide;
Methyl 4-(8-chloro-lO,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2E-butenoate;
4-(8-chloro-lO,11-dihydrodibenz[b,f]oxazepin-10-yl)~
N-[2-(dimethylamino)ethyl]-4-oxo-2E-butenamide, monohydrochloride;
8-chloro-γ-oxo-N-(4-pyridinylmethyl)dibenz[b,f]- [1,4]
oxazepine-10(11)-butanamide;
8-chloro-N-oxo-N-[2-(dimethylamino)ethyl]-γ-oxodibenz- [b,f]
 [1,4]oxazepine-10(11)-butanamide;
4-(8-chloro-lO,11-dihydrodibenz[b,f]oxazepin-10-yl)- 4-oxo-N-(4-pyridinylmethyl)-2E-butenamide; or
4-(8-chloro-lO,11-dihydrodibenz[b,f]oxazepin-10-yl)-
4-oxo-N-(4-pyridinylmethyl)-2E-butenamide, monohydrochloride.
34. A method for treating diarrhea in an animal comprising administering to said animal a therapeutically-effective amount of a compound of Claim 1. 


 35. The method of Claim 34 wherein the compound is:
4-(8-chloro-10,11-dihydrodibenz[b,f]oxazepin-10-yl)-
N-[2-(dimethylamino)ethyl]-4-oxo-2E-butenamide, monohydrochloride;
4-(8-chloro-lO,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butanoic acid;
Butyl 4-(8-chloro-10,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butenoate;
Butyl 4-(8-chloro-10,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2E-butenoate;
N-butyl-4-(8-chloro-10,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butenamide;
Methyl 4-(8-chloro-10,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2E-butenoate;
4-(8-chloro-10,11-dihydrodibenz[b,f]oxazepin-10-yl)-
N-[2-(dimethylamino)ethyl]-4-oxo-2E-butenamide, monohydrochloride;
8-chloro-γ-oxo-N-(4-pyridinylmethyl)dibenz[b,f]- [1,4]
oxazepine-10(11)-butanamide;
8-chloro-N-oxo-N-[2-(dimethylamino)ethyl]-γ-oxodibenz- [b,f]
 [1,4]oxazepine-10(11)-butanamide;
-(8-chloro-10,11-dihydrodibenz[b,f]oxazepin-lO-yl)- 4-oxo-N-(4-pyridinylmethyl) -2E-butenamide; or
4-(8-chloro-10,11-dihydrodibenz[b,f]oxazepin-10-yl)-
4-oxo-N-(4-pyridinylmethyl)-2E-butenamide, monohydrochloride. 


 36. A method for treating dysmenorrhea in an animal comprising administering to said animal a therapeutically-effective amount of a compound of Claim 1.
37. The method of Claim 36 wherein the compound is:
4-(8-chloro-10,11-dihydrodibenz[b,f]oxazepin-10-yl)-
N-[2-(dimethylamino)ethyl]-4-oxo-2E-butenamide, monohydrochloride;
4-(8-chloro-lO,ll-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butanoic acid;
Butyl 4-(8-chloro-lO,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butenoate;
Butyl 4-(8-chloro-lO,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2E-butenoate;
N-butyl-4-(8-chloro-lO,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butenamide;
Methyl 4-(8-chloro-lO,11-dihydrodibenz[b ,f]- oxazepin-10-yl)-4-oxo-2E-butenoate;
4-(8-chloro-lO,11-dihydrodibenz[b,f]oxazepin-10-yl)-
N-[2-(dimethylamino)ethyl]-4-oxo-2E-butenamide, monohydrochloride;
8-chloro-γ-oxo-N-(4-pyridinylmethyl)dibenz[b,f]- [1,4]
oxazepine-10(11)-butanamide;
8-chloro-N-oxo-N-[2-(dimethylamino)ethyl]-γ-oxodibenz- [b,f]
[l,4]oxazepine-10(11)-butanamide; 



4-(8-chloro-10,11-dihydrodibenz[b,f]oxazepin-10-yl)- 4-oxo-N-(4-pyridinylmethyl)-2E-butenamide; or
4-(8-chloro-10,11-dihydrodibenz[b,f]oxazepin-10-yl)-
4-oxo-N-(4-pyridinylmethyl)-2E-butenamide, monohydrochloride.
38. A method for treating osteoporosis in an animal comprising administering to said animal a therapeutically-effective amount of a compound of Claim 1.
39. The method of Claim 38 wherein the compound is:
4-(8-chloro-10,ll-dihydrodibenz[b,f]oxazepin-10-yl) N-[2-(dimethylamino)ethyl]
-4-oxo-2E-butenamide, monohydrochloride;
4-(8-chloro-lO,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butanoic acid;
Butyl 4-(8-chloro-10,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butenoate;
Butyl 4-(8-chloro-10,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2E-butenoate;
N-butyl-4-(8-chloro-10,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butenamide;
Methyl 4-(8-chloro-10,ll-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2E-butenoate; 



 4-(8-chloro-10,11-dihydrodibenz[b,f]oxazepin-10-yl)-
N-[2-(dimethylamino)ethyl]-4-oxo-2E-butenamide, monohydrochloride;
8-chloro-γ-oxo-N-(4-pyridinylmethyl)dibenz[b,f]- [1,4]
oxazepine-10(11)-butanamide;
8-chloro-N-oxo-N-[2-(dimethylamino)ethyl]-γ-oxodibenz- [b,f]
 [1,4]oxazepine-10(11)-butanamide;
4-(8-chloro-lO,ll-dihydrodibenz[b,f]oxazepin-10-yl)- 4-oxo-N-(4-pyridinylmethyl)-2E-butenamide; or
4-(8-chloro-10,11-dihydrodibenz[b,f]oxazepin-10-yl)-
4-oxo-N-(4-pyridinylmethyl)-2E-butenamide, monohydrochloride.
40. A method for treating convulsions in an animal comprising administering to said animal a therapeutically-effective amount of a compound of Claim 1.
41. The method of Claim 40 wherein the compound is:
4-(8-chloro-lO,11-dihydrodibenz[b,f]oxazepin-10-yl)-
N-[2-(dimethylamino)ethyl]-4-oxo-2E-butenamide, monohydrochloride;
4-(8-chloro-lO,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butanoic acid;
Butyl 4-(8-chloro-10,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butenoate; 



 Butyl 4-(8-chloro-10,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2E-butenoate;
N-buty1-4-(8-chloro-lO,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butenamide;
Methyl 4-(8-chloro-10,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2E-butenoate;
4-(8-chloro-10,ll-dihydrodibenz[b,f]oxazepin-10-yl)-
N-[2-(dimethylamino)ethyl]-4-oxo-2E-butenamide, monohydrochloride;
8-chloro-γ-oxo-N-(4-pyridinylmethyl)dibenz[b,f]- [1,4]
oxazepine-10(11)-butanamide;
8-chloro-N-oxo-N-[2-(dimethylamino)ethyl]
-γ-oxodibenz- [b,f] [l,4]
oxazepine-10(11)-butanamide;
4-(8-chloro-10,11-dihydrodibenz[b,f]oxazepin-10-yl)- 4-oxo-N-(4-pyridinylmethyl)-2E-butenamide; or
4-(8-chloro-10,11-dihydrodibenz[b,f]oxazepin-10-yl)-
4-oxo-N-(4-pyridinylmethyl)-2E-butenamide, monohydrochloride.
42. A method for treating ischemia in an animal comprising administering to said animal a therapeutically-effective amount of a compound of Claim 1.
43. The method of Claim 42 wherein the compound is:
4-(8-chloro-10,ll-dihydrodibenz[b,f]oxazepin-10-yl) N-[2-(dimethylamino)ethyl]
-4-oxo-2E-butenamide, monohydrochloride; 


 4-(8-chloro-10,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butanoic acid;
Butyl 4-(8-chloro-lO,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butenoate;
Butyl 4-(8-chloro-lO,ll-dihydrodibenz[b, ]- oxazepin-10-yl)-4-oxo-2E-butenoate;
N-buty1-4-(8-chloro-lO,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butenamide;
Methyl 4-(8-chloro-10,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2E-butenoate;
4-(8-chloro-lO,11-dihydrodibenz[b,f]oxazepin-10-yl)-
N-[2-(dimethylamino) thyl]-4-oxo-2E-butenamide, monohydrochloride;
8-chloro-γ-oxo-N-(4-pyridinylmethyl)dibenz[b,f]- [1,4]
oxazepine-10(11)-butanamide;
8-chloro-N-oxo-N-[2-(dimethylamino)ethyl]-γ-oxodibenz- [b,f]
 [1, ]oxazepine-10(11)-butanamide;
4-(8-chloro-10,11-dihydrodibenz[b,f]oxazepin-10-yl)• 4-oxo-N-(4-pyridinylmethyl)-2E-butenamide; or
4-(8-chloro-10,11-dihydrodibenz[b,f]oxazepin-10-yl)-
4-oxo-N-(4-pyridinylmethyl)-2E-butenamide, monohydrochloride.
44. A method for treating urinary incontinence in an animal comprising administering to said animal a therapeutically-effective amount of a compound of Claim 1. 


 45. The method of Claim 44 wherein the compound is:
4-(8-chloro-10,11-dihydrodibenz[b,f]oxazepin-lθ-yl)-
N-[2-(dimethylamino)ethyl]-4-oxo-2E-butenamide, monohydrochloride;
4-(8-chloro-10,ll-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butanoic acid;
Butyl 4-(8-chloro-l0,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butenoate;
Butyl 4-(8-chloro-10, 11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2E-butenoate;
N-butyl-4-(8-chloro-lO,ll-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butenamide;
Methyl 4-(8-chloro-10,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2E-butenoate;
4-(8-chloro-10,11-dihydrodibenz[b,f]oxazepin-10-yl)-
N-[2-(dimethylamino)ethyl]-4-oxo-2E-butenamide, monohydrochloride;
8-chloro-γ-oxo-N-(4-pyridinylmethyl)dibenz[b,f]- [1,4]
oxazepine-10(11)-butanamide;
8-chloro-N-oxo-N-[2-(dimethylamino)ethyl]-γ-oxodibenz- [b,f]
 [1,4]oxazepine-10(11) -butanamide;
-(8-chloro-10,11-dihydrodibenz[b,f]oxazepin-10-yl)- 4-oxo-N-(4-pyridinylmethyl)-2E-butenamide; or 



 4-(8-chloro-10,11-dihydrodibenz[b,f]oxazepin-10-yl)-
4-oxo-N-(4-pyridinylmethyl)-2E-butenamide, monohydrochloride.
46. A method for treating gastric hypermotility in an animal comprising administering to said animal a therapeutically-effective amount of a compound of Claim 1.
47. The method of Claim 46 wherein the compound is:
4-(8-chloro-lO,11-dihydrodibenz[b,f]oxazepin-10-yl)~
N-[2-(dimethylamino)ethyl]-4-oxo-2E-butenamide, monohydrochloride;
4-(8-chloro-lO,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butanoic acid;
Butyl 4-(8-chloro-lO,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butenoate;
Butyl 4-(8-chloro-10,ll-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2E-butenoate;
N-butyl-4-(8-chloro-lO,11-dihydrodibenz[b,f]- oxazepin-10-y1)-4-oxo-2Z-butenamide;
Methyl 4-(8-chloro-lO ,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2E-butenoate;
4-(8-chloro-lO,ll-dihydrodibenz[b,f]oxazepin-10-yl)-
N-[2-(dimethylamino)ethyl]-4-oxo-2E-butenamide, monohydrochloride;
8-chloro-γ-oxo-N-(4-pyridinylmethyl)dibenz[b,f]- [1,4]
oxazepine-10(11)-butanamide; 


 8-chloro-N-oxo-N-[2-(dimethylamino)ethyl]-γ-oxodibenz- [b,f]
 [l,4]oxazepine-10(11)-butanamide;
4-(8-chloro-lO,11-dihydrodibenz[b,f]oxazepin-10-yl)- 4-oxo-N-(4-pyridinylmethyl)-2E-butenamide; or
4-(8-chloro-lO,11-dihydrodibenz[b,f]oxazepin-10-yl)-
4-oxo-N-(4-pyridinylmethyl)-2E-butenamide, monohydrochloride.
48. A method for treating irritable bowel syndrome in an animal comprising administering to said animal a therapeutically-effective amount of a compound of Claim 1.
49. The method of Claim 48 wherein the compound is:
4-(8-chloro-10,11-dihydrodibenz[b,f]oxazepin-10-yl)-
N-[2-(dimethylamino)ethyl]-4-oxo-2E-butenamide, monohydrochloride;
4-(8-chloro-10,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butanoic acid;
Butyl 4-(8-chloro-10,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butenoate;
Butyl 4-(8-chloro-10,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2E-butenoate;
N-butyl-4-(8-chloro-10,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2Z-butenamide;
Methyl 4-(8-chloro-lO,11-dihydrodibenz[b,f]- oxazepin-10-yl)-4-oxo-2E-butenoate; 



 4-(8-chloro-lO,ll-dihydrodibenz[b, ]oxazepin-10-yl)-
N-[2-(dimethylamino)ethyl]-4-oxo-2E-butenamide, monohydrochloride;
8-chloro-γ-oxo-N-(4-pyridinylmethyl)dibenz[b,f]- [1,4]
oxazepine-10(11)-butanamide;
8-chloro-N-oxo-N-[2-(dimethylamino)ethyl]-γ-oxodibenz- [b,f]
 [1,4]oxazepine-10(11)-butanamide;
-(8-chloro-lO,11-dihydrodibenz[b,f]oxazepin-10-yl)- 4-oxo-N-(4-pyridinylmethyl)-2E-butenamide; or
4-(8-chloro-10,11-dihydrodibenz[b,f]oxazepin-10-yl)-
4-oxo-N-(4-pyridinylmethyl)-2E-butenamide, monohydrochloride. 

</CLAIMS>
</TEXT>
</DOC>
